Physician profile
Neil Coskun
NPI 1093814063
$6,881.86
in general payments reported to CMS, 2019-2025
51 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $1,159 · 2021: $1,677 · 2022: $1,090 · 2023: $737 · 2024: $576 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,791.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $724.60 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $557.66 | 2019-2024 | Farxiga |
| Abbvie INC. | $532.83 | 2019-2025 | Ubrelvy |
| Pfizer INC. | $364.58 | 2019-2025 | |
| Abbott Laboratories | $348.78 | 2019-2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $304.57 | 2019-2021 | |
| Lilly USA, LLC | $290.31 | 2019-2025 | Mounjaro, Kisunla |
| Esperion Therapeutics, INC. | $283.27 | 2020-2024 | Nexletol |
| Amarin Pharma, INC. | $267.75 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.92 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $238.59 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $225.29 | 2019-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $210.32 | 2019-2022 | |
| Orexo US, INC. | $202.07 | 2019-2023 | Zubsolv |
| Allergan, INC. | $188.95 | 2019-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Coskun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.